Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis (MS)
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS).
- Trial name
- NCT03972306
- Testing
- Ocrelizumab, rHuPH20
- Where
- 18 sites in United States
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Multiple Sclerosis
Zoledronic Acid in MS-patients With Osteoporosis
This study is designed to evaluate the efficacy and safety of zoledronic acid 5 mg intravenous (i.v.) relative to placebo in Multiple Sclerosis (MS) patients with osteoporosis and to support the optimal use of zoledronic acid for…
- Trial name
- EXALT (NCT01166178)
- Testing
- Zoledronic Acid, Calcium and Vitamin D combination
- Where
- 15 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis
Relapsing-remitting Multiple Sclerosis
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
Phase IV, proof-of-concept, randomized, open-label, multi-center, two-arm, 9-month study to evaluate the neuroprotective effects of Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of…
- Trial name
- PRTOECT (NCT00771043)
- Testing
- TYSABRI and AVONEX
- Sponsor
- Biogen
Multiple Sclerosis
Avonex 15 Year Long Term Follow-up Study
The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients…
- Trial name
- 15yASSURANCE (NCT00525343)
- Where
- 4 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
BEYOND Pilot Study
The purpose of this study is to valuate safety and tolerability of Betaseron.
- Trial name
- NCT00893217
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046)
- Where
- 14 sites in United States
- Volunteers
- 71 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing Remitting
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
This is a randomized, double-blind, parallel group study comparing two doses of INT131( 3 mg and 1 mg) administered orally (PO) daily (QD) versus placebo 1 tablet PO QD in subjects with treatment-naïve RRMS for ≤ 3 years.
- Trial name
- NCT02638038
- Testing
- INT131
- Volunteers
- 228 people
- Sponsor
- InteKrin Therapeutics, Inc.
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
- Trial name
- MS (NCT06800404)
- Testing
- Autologous HB-adMSCs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hope Biosciences Research Foundation
Spinal Cord Injuries, Multiple Sclerosis
GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders
The purpose of this study is to evaluate the rate of occurrence of urethral pain in female patients with neurological vesico-sphincter disorders whilst performing self-catheterization using GentleCath™ Air catheters.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Parkinsonian Disorders, Allodynia
- Trial name
- FollowAir (NCT04847609)
- Testing
- GentleCath™ Air catheter
- Sponsor
- ConvaTec Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS)…
- Trial name
- RELIEF (NCT02064816)
- Testing
- Rebif®
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)
This will be prospective, multicentre, observational study. Patients who will initiate treatment with IFNβ-1b (Betaferon) will be followed up to 6 months. Baseline visit (visit 0) i.e.
- Trial name
- INFLUENCE (NCT01706055)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Poland
- Volunteers
- 629 people
- Sponsor
- Bayer
Relapsing Multiple Sclerosis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
- Trial name
- NCT07211633
- Testing
- Ublituximab
- Where
- 48 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 360 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis, Relapsing-Remitting
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects with relapsing-remitting multiple…
- Trial name
- RECYCLINE (NCT01134627)
- Testing
- Minocycline
- Where
- Denmark
- Volunteers
- 305 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS)
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.
- Trial name
- SEPROS (NCT06157086)
- Testing
- ofatumumab
- Where
- 49 sites in France
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical…
- Trial name
- START (NCT00461396)
- Testing
- Interferon-1beta (Betaseron, BAY86-5046)
- Where
- 19 sites in United States
- Volunteers
- 104 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing Remitting
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of this improved formulation (with regards…
- Trial name
- STAR (NCT01080027)
- Testing
- Rebif® New Formulation
- Where
- Greece
- Volunteers
- 254 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon
In this study researchers wanted to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with Betaferon using the myBETAapp which includes the elements to what extent taking medication…
- Trial name
- NCT03808142
- Testing
- myBETAapp, PEAK, Betaferon, BAY86-5046
- Where
- Germany
- Volunteers
- 79 people
- Sponsor
- Bayer
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
- Trial name
- COURAGE-ALS (NCT04944784)
- Testing
- Reldesemtiv
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 489 people
- Sponsor
- Cytokinetics
Relapsing-remitting Multiple Sclerosis, RRMS
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with…
- Trial name
- NCT01051817
- Testing
- AIN457
- Where
- 16 sites in Czechia, Russia and 1 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period.
- Trial name
- HBMS01 (NCT05116540)
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences Research Foundation
Multiple Sclerosis
Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis
The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis.
- Trial name
- NHS-MS-EGYPT (NCT06346704)
- Testing
- Digital HealthTechnology
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- SYSNAV